Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...

Blood Transfusion

Blood Transfusion

Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Hematopoiesis

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

Role of Hematopoietic Growth Factors

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...

Blood Typing

Blood Typing

Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target antigens A,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinically observed RASA1 missense mutants exhibit diverse RasGAP protein behaviors in vitro.

The Journal of biological chemistry·2026

Same author

Dual recruitment of two CCM2 molecules to KRIT1 suppresses KLF4 expression.

Nature communications·2026

Same author

Structural basis for MEKK2 dimerization and substrate recognition.

Nature communications·2025

Same author

Clinically observed <i>RASA1</i> missense mutants exhibit diverse RasGAP protein behaviors.

bioRxiv : the preprint server for biology·2025

Same author

Optimized conditions for GTP loading of Ras.

The Journal of biological chemistry·2025

Same author

Nickel Binding to the c-Src SH3 Domain Facilitates Crystallization.

Protein and peptide letters·2025

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

JAK3: a two-faced player in hematological disorders.

Melanie G Cornejo¹, Titus J Boggon, Thomas Mercher

¹Harvard Medical School, Boston, MA 02115, USA.

The International Journal of Biochemistry & Cell Biology

|September 15, 2009

Summary

Janus kinase 3 (JAK3) is crucial for immune function and its mutations cause severe combined immunodeficiency (SCID). Aberrant JAK3 activation is linked to hematological malignancies, suggesting JAK3 inhibition as a potential therapy.

More Related Videos

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

Related Experiment Videos

Last Updated: Jun 20, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

Area of Science:

Biochemistry
Immunology
Oncology

Background:

Janus kinase 3 (JAK3) is a non-receptor tyrosine kinase primarily in hematopoietic cells.
JAK3 is vital for signal transduction of common gamma chain cytokine receptors, essential for T cell development and hematopoiesis.
Inactivating JAK3 mutations lead to severe combined immunodeficiency (SCID) in humans and mice.

Purpose of the Study:

To review the structure and function of JAK3.
To examine the emerging role of JAK3 activation in hematological malignancies.
To assess the therapeutic potential of JAK3 inhibition in these diseases.

Main Methods:

Literature review of JAK3 structure, function, and mutations.
Analysis of data linking JAK3 activation to specific hematological cancers.
Discussion of preclinical and clinical evidence for JAK3 inhibitors.

Main Results:

JAK3's established role in immune deficiency through inactivating mutations.
Evidence implicating abnormal JAK3 activation in acute megakaryoblastic leukemia (AMKL) and cutaneous T cell lymphoma (CTCL).
JAK3 activation presents a potential therapeutic target in specific hematological malignancies.

Conclusions:

JAK3 plays a dual role in hematopoiesis: essential for normal function and implicated in malignancy when aberrantly activated.
Targeting JAK3 may offer a novel therapeutic strategy for challenging hematological malignancies.
Further research is warranted to validate JAK3 inhibition's clinical relevance.